DALLAS--(BUSINESS WIRE)--Lantern Pharma (NASDAQ: LTRN), an artificial intelligence (AI) company dedicated to developing cancer therapies and transforming the cost, pace, and timeline of oncology drug ...
SAN FRANCISCO, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for dermal, ...
For the initial safety lead-in portion of the Phase 2 study, which involved 7 patients, all patients received the LP-300 drug candidate with pemetrexed and carboplatin intravenously2. Preliminary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback